Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Latanoprost Vs. Timolol
NCT00579969 · University of Nebraska · PHASE2 · terminated · last registry update 2023-12-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study stopped and data not analyzed” | – | Registry record, University of Nebraska |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-31Phase 3 first posted: Santen Pharmaceutical Co., Ltd., DE-117B Eye Drops + Latanoprost (NCT06666855)
- 2024-10-15Results posted on the registry: Glaukos Corporation, Travoprost Intracameral Implant exchanged at Month 12 + Travoprost Intracameral Implant exchanged at Month 3 (NCT06582732)
- 2024-10-01Results posted on the registry: Ocular Therapeutix, Inc., OTX-TIC (NCT04360174)
- 2024-08-23Also stopped (terminated): CT Glaucoma Associates, dorzolamide/timolol (NCT06369077)
- 2024-08-21Also stopped (withdrawn): Nova Scotia Health Authority, Prostagladin (NCT01704989)
- 2024-07-05Also stopped (terminated): Laboratorios Sophia S.A de C.V., PRO-067 + GAAP Ofteno® (NCT02801617)
- 2024-05-28Results posted on the registry: Santen SAS, DE-130A + Xalatan® (NCT04133311)
- 2024-05-10Also stopped (suspended): JeniVision, Inc., JV-GL1 + Latanoprost 0.005% Ophthalmic Solution (NCT04761705)
- 2024-05-10Results posted on the registry: AbbVie, Bimatoprost SR + Sham Bimatoprost SR (NCT02507687)
- 2024-04-03Results posted on the registry: Aerie Pharmaceuticals, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution (NCT05283395)
- 2024-03-15Results posted on the registry: Santen Pharmaceutical Co., Ltd., DE-117 + Latanoprost ophthalmic solution (NCT02981446)
- 2024-03-04Also stopped (withdrawn): Bausch & Lomb Incorporated, Latanoprostene Bunod + Placebo (NCT04140279)
- 2023-12-05Also stopped (terminated): Alcon Research, Travoprost 0.004% + Brinzolamide 1.0% + Travoprost 0.004% + Tears Natural (NCT00758342)
- 2023-11-21Results posted on the registry: Laboratoires Thea, Bimatoprost + Lumigan® (NCT03825380)
- 2023-09-29Phase 3 first posted: Glaukos Corporation, iDose TR (NCT06061718)
- 2023-09-26Results posted on the registry: Glaukos Corporation, G2-TR intraocular implant containing travoprost + Sham surgery + active-comparator eye drops (NCT03868124)
- 2023-09-26Results posted on the registry: Glaukos Corporation, Travoprost (NCT04615403)
- 2023-09-14Results posted on the registry: Glaukos Corporation, G2-TR intraocular implant containing travoprost + Sham surgery + active-comparator eye drops (NCT03519386)
- 2023-09-13Results posted on the registry: Mati Therapeutics Inc., Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug (NCT04962009)
- 2023-08-30Results posted on the registry: Santen Inc., DE-117 Ophthalmic Solution (NCT03697811)
- 2023-08-09Results posted on the registry: Glaukos Corporation, Travoprost Intraocular Implant, high elution + Travoprost Intraocular Implant, low elution (NCT02754596)
- 2023-07-10Phase 3 first posted: Nicox Ophthalmics, Inc., NCX 470 + Placebo (NCT05938699)
- 2023-06-08Results posted on the registry: AbbVie, Bimatoprost SR + LUMIGAN (NCT04285580)
- 2023-05-25Results posted on the registry: EyePoint Pharmaceuticals, Inc., Latanoprost ophthalmic solution + AKB-9778 4% (NCT04405245)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision